INDEMNIFICATION AGREEMENTIndemnification Agreement • October 29th, 2019 • I-Mab • Pharmaceutical preparations
THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made as of , 2019 by and between I-MAB, an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands (the “Company”), and ([Passport/ID] Number ) (the “Indemnitee”).
EMPLOYMENT AGREEMENTEmployment Agreement • October 29th, 2019 • I-Mab • Pharmaceutical preparations • New York
This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of _________, 2019 by and between I-MAB, an exempted company incorporated and existing under the laws of the Cayman Islands (the “Company”) and ____________, an individual with _______ [passport/ID number] __________________ (the “Executive”).
CD38 PRODUCT COLLABORATION AGREEMENTCd38 Product Collaboration Agreement • October 29th, 2019 • I-Mab • Pharmaceutical preparations • Hong Kong
This CD38 PRODUCT COLLABORATION AGREEMENT (the “Agreement”) is entered into on January 22, 2018 (the “Effective Date”) between I-Mab, a company organized and existing under the laws of Cayman Islands and having its registered address at P. O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1-1205 Cayman Islands (“I-Mab”), and EVEREST MEDICINES LIMITED, a company organized and existing under the laws of Cayman Islands and having its registered address at 4th Floor, Harbour Place, 103 South Church Street, P.O. Box 10240, Grand Cayman KY1-1002, Cayman Islands (“Everest”). Everest and I-Mab are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
FERRING INTERNATIONAL CENTER SA and I-MAB LICENSE AND SUBLICENSE AGREEMENTLicense and Sublicense Agreement • October 29th, 2019 • I-Mab • Pharmaceutical preparations
THIS LICENSE AND SUBLICENSE AGREEMENT (this “Agreement”) is effective as of 4th of November 2016 (the “Effective Date”), and is by and between FERRING INTERNATIONAL CENTER SA, a company organised and existing under the laws of Switzerland and having its principal place of business at Chemin de la Vergognausaz 50 CH-1162 Saint-Prex Switzerland (“Ferring”) and I-MAB, a company organised and existing under the laws of Cayman Islands and having its principal place of business at Floor 4, Willow House, Cricket Square, P 0 Box 2804, Grand Cayman KY1-1112, Cayman Islands, (“I-MAB”). Each party individually may be referred to herein as a “Party” and collectively both parties may be referred to herein as the “Parties.”
Re-organization Framework AgreementRe-Organization Framework Agreement • October 29th, 2019 • I-Mab • Pharmaceutical preparations
Re-organization Framework AgreementRe-Organization Framework Agreement • October 29th, 2019 • I-Mab • Pharmaceutical preparations
This Re-organization Framework Agreement (hereinafter referred to as “this Agreement”) is signed on April 18, 2018 in Tianjin by and among:
FOURTH AMENDED AND RESTATED SHAREHOLDERS AGREEMENTShareholder Agreement • October 29th, 2019 • I-Mab • Pharmaceutical preparations • Hong Kong
Each of the foregoing parties is referred to herein individually as a “Party” and collectively as the “Parties”. The Series A Investors, the Series B Investors, the Series C Investors and the Series C-1 Investors are referred to herein collectively as the “Investors”.
GENEXINE, INC. AND I-MAB INTELLECTUAL PROPERTY LICENSE AGREEMENT DATED DECEMBER 22, 2017Intellectual Property License Agreement • October 29th, 2019 • I-Mab • Pharmaceutical preparations
Genexine and I-Mab have agreed to establish a cooperation relationship with each other, under which Genexine, as the sole and exclusive owner of all the patents, patent applications, know-hows, data and information (the “Licensed Intellectual Properties”), which relate to the Licensed Product (as defined below) and are limited to those listed on Exhibit A attached hereto and may be updated from time to time during the term of this Agreement upon mutual consents of the Parties, intends to grant the License (as defined below) of the Licensed Intellectual Properties to I-Mab so that I-Mab can engage in pre-clinical/clinical development, manufacturing, sale and distribution of the Licensed Product in the Territory (as defined below). I-Mab intends to accept the License of the Licensed Intellectual Properties from Genexine in accordance with this Agreement.
FRAMEWORK AGREEMENTFramework Agreement • October 29th, 2019 • I-Mab • Pharmaceutical preparations • Hong Kong
Supplement to the Re-organization Framework AgreementRe-Organization Framework Agreement • October 29th, 2019 • I-Mab • Pharmaceutical preparations
This Supplement to the Re-organization Framework Agreement (hereinafter referred to as the “Supplementary Agreement”) is signed on May 31, 2018 in Tianjin by and among:
COLLABORATION AGREEMENT between ABL Bio and I-Mab Dated July 26, 2018Collaboration Agreement • October 29th, 2019 • I-Mab • Pharmaceutical preparations • New York
This Collaboration Agreement (“Agreement”) is made and entered into as of the date first written above (the “Effective Date”) by and between ABL Bio having a business address at 16, Daewangpangyo-ro 712beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488, Republic of Korea (“ABL Bio”) and I-Mab, having a business address at P. O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1-1205 Cayman Islands (“I-Mab ”). For purposes of this Agreement, ABL Bio and I-Mab are each referred to individually as a “Party” and together the “Parties.”
